NHS Alzheimer’s Treatments: Is the NHS Ready for a New Era of Dementia Care?
The arrival of new NHS Alzheimer’s treatments has the potential to mark one of the most important changes in dementia care for decades. Medicines such as lecanemab and donanemab have demonstrated that it is possible to target an underlying disease process in Alzheimer’s rather than solely managing symptoms. Yet this scientific progress also raises an equally important question for the UK healthcare system: is the NHS equipped to deliver these types of treatments at scale?
Recent reporting has drawn renewed attention to concerns surrounding NHS readiness for breakthrough Alzheimer’s medicines. The challenge is considerably more complex than simply purchasing a new drug. Disease-modifying treatments can require earlier diagnosis, specialist assessment, amyloid testing, MRI capacity, infusion services, monitoring and appropriately trained clinical teams.
For NHS organisations, commissioners, memory services, radiology departments and healthcare procurement teams, this represents a potentially significant change in how early Alzheimer’s disease may be diagnosed, monitored and treated in the future.
Why New Alzheimer’s Treatments Are So Significant
For many years, Alzheimer’s treatment has largely focused on helping people manage symptoms. The emergence of lecanemab and donanemab is important because these medicines are designed to target amyloid, a protein associated with Alzheimer’s disease.
They are not cures, and patients receiving them can still experience worsening cognitive function. However, clinical trials have shown that progression can be slowed in some people with early-stage disease.
This distinction matters.
Slowing progression could potentially give eligible patients more time during which symptoms remain relatively mild and independence can be maintained. Alzheimer’s Research UK explains that both lecanemab and donanemab have been licensed for use in the UK, although neither is currently routinely available through the NHS.
Further information about emerging Alzheimer’s treatments can be found at:
New Alzheimer’s treatments – Alzheimer’s Research UK
The development of disease-modifying treatments therefore represents scientific progress, but translating that progress into routine healthcare presents a much wider operational challenge.
Why NHS Alzheimer’s Treatments Require More Than a New Medicine
Introducing NHS Alzheimer’s treatments would involve much more than prescribing medication following a conventional dementia diagnosis.
NHS England has previously outlined what a pathway for disease-modifying Alzheimer’s treatments could involve. Patients presenting with early cognitive symptoms may initially be assessed in primary care before progressing to more comprehensive cognitive and diagnostic testing.
For suitable patients, the pathway may require a baseline MRI scan followed by either PET-CT imaging or a lumbar puncture to establish whether beta-amyloid is present.
Patients who meet the appropriate criteria could then progress to treatment, which may involve repeated intravenous infusions alongside scheduled MRI scans to monitor for potential adverse effects.
The NHS England information is available at:
NHS England » Dementia programme and preparation for new Alzheimer’s disease modifying treatments
This illustrates why discussions about readiness are so important. A breakthrough medicine does not operate independently from the healthcare system around it. Diagnostic services, radiology capacity, infusion facilities, clinical staffing, appointment availability and monitoring systems all become part of the treatment pathway.
Earlier Diagnosis Could Become Increasingly Important
One of the most significant implications is the importance of identifying Alzheimer’s disease at an early stage.
The NHS currently advises people who are concerned about memory, planning or organisational difficulties to speak to their GP. Memory problems can have numerous causes, so assessment is necessary before Alzheimer’s disease can be diagnosed.
Specialist assessment can involve cognitive testing and, where appropriate, CT or MRI brain imaging. The NHS emphasises that accurate and timely diagnosis can help people access appropriate treatment and support while giving individuals and families more opportunity to plan for the future.
More information is available from the NHS at:
Alzheimer’s disease – Diagnosis – NHS
With disease-modifying medicines, timely diagnosis becomes particularly relevant because the currently licensed treatments are intended for people at relatively early stages of Alzheimer’s disease rather than those with advanced disease.
Healthcare systems therefore need to consider not only how treatments could be administered, but also whether patients can move through assessment and diagnosis quickly enough to identify those who may potentially be eligible.
The Diagnostic Capacity Challenge
The diagnostic requirements associated with new Alzheimer’s medicines could place additional demands on already complex healthcare pathways.
A traditional clinical assessment alone may not provide all the information necessary to determine whether a person is suitable for a disease-modifying treatment. Confirmation of amyloid pathology can require specialist investigations such as PET imaging or cerebrospinal fluid testing.
MRI also plays an important role.
Patients may require MRI before treatment and further imaging during treatment to monitor for adverse effects. This creates additional demand across radiology services and means that dementia care could increasingly intersect with diagnostic imaging, neurology, pharmacy, infusion services and other specialist departments.
This is why preparation for future Alzheimer’s treatments must be considered across the entire patient pathway rather than solely within memory clinics.
Treatment Delivery and Monitoring
Another major consideration is how the medicines are administered.
Lecanemab requires intravenous infusion every two weeks, while donanemab is administered every four weeks under the currently licensed treatment approaches. These appointments require clinical space, staff time, medicine preparation and appropriate monitoring.
There are also important safety considerations.
These treatments can be associated with amyloid-related imaging abnormalities, commonly referred to as ARIA, which can include swelling or bleeding in the brain. Appropriate patient selection and MRI monitoring are therefore important parts of treatment.
The challenge facing healthcare organisations is consequently both clinical and logistical.
Services may need to consider how patients move safely between diagnosis, imaging, pharmacy, infusion and follow-up appointments without introducing unnecessary delays or creating additional pressure on existing services.
NICE and the Question of NHS Access
Another major factor is cost effectiveness.
Following further consideration in 2026, NICE’s draft recommendations continued not to recommend lecanemab or donanemab for routine NHS use for the populations covered by their marketing authorisations. NICE has highlighted both the benefits demonstrated in clinical studies and the substantial costs associated with treatment and its delivery.
For lecanemab in particular, NICE has noted the additional costs created by hospital infusions and intensive monitoring for potential side effects.
The latest NICE information can be accessed at:
This is an important distinction when discussing NHS readiness. The immediate question is not simply whether these particular medicines will become routinely available. The broader issue is whether dementia services are sufficiently prepared for a future in which disease-modifying therapies become a more established part of clinical practice.
More Alzheimer’s medicines are already being investigated. The infrastructure developed today could therefore influence the NHS’s ability to adopt future treatments.
Preparing Healthcare Environments for Changing Dementia Care
While drug development attracts much of the attention, high-quality dementia care continues to depend on the environment surrounding the patient.
People living with dementia can experience problems with memory, orientation, communication and understanding their surroundings. Healthcare environments should therefore be designed to support clarity, familiarity and independence wherever reasonably possible.
Simple environmental aids can form part of this wider approach.
Niche Healthcare supplies a User Friendly Dementia Clock designed to provide a clear visual reference for time and support orientation in healthcare and care environments. Product information is available at:
User Friendly Dementia Clock – Niche Healthcare
Sensory and therapeutic environments may also form part of wider patient-centred care strategies. Niche Healthcare supplies specialist healthcare and sensory products for use across appropriate clinical and therapeutic environments, including the UV Bubble Wall:
UV Bubble Wall in Healthcare – Niche Healthcare
Products such as these should not be viewed as treatments for Alzheimer’s disease. Instead, they can form part of a broader consideration of how healthcare environments are organised to support comfort, orientation, engagement and patient experience.
Procurement Will Have a Role in the Future of Dementia Services
The discussion surrounding breakthrough Alzheimer’s medicines also demonstrates how closely clinical innovation and healthcare procurement are connected.
If treatment pathways evolve, healthcare organisations may require additional diagnostic capacity, infusion equipment, patient monitoring resources, appropriate furniture, clinical consumables, storage solutions and dementia-friendly environmental products.
Procurement teams therefore play an important role in translating clinical requirements into operationally viable services.
This requires careful product assessment. Healthcare products should be selected according to their intended purpose, applicable regulatory requirements, infection prevention considerations, compatibility with existing clinical workflows and the specific requirements of the organisation.
Niche Healthcare supports NHS trusts, hospitals, private healthcare providers, laboratories and other healthcare organisations with healthcare supplies, specialist product sourcing and procurement support.
Further information about the wider Niche Healthcare range is available at:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
Safety, Hygiene and Compliance Remain Essential
Innovation should never reduce the importance of fundamental healthcare standards.
Any expansion of specialist dementia services would need to maintain robust infection prevention procedures, particularly where patients attend healthcare environments regularly for intravenous treatment.
Infusion areas, diagnostic environments and patient-facing equipment must be managed according to appropriate local infection prevention policies and manufacturer instructions. Equipment should be cleaned and maintained correctly, and clinical teams must have access to appropriate consumables and protective equipment.
Niche Healthcare supplies products across areas including infection prevention, clinical consumables, medical devices, healthcare furniture, rehabilitation, laboratory supplies and specialist healthcare equipment.
Healthcare organisations can explore the wider range at:
Essential Healthcare Catalogues – Niche Office Solutions Ltd
What Could This Mean for NHS Dementia Services?
The development of disease-modifying Alzheimer’s medicines should be viewed as part of a longer transformation rather than a single treatment launch.
Healthcare organisations may increasingly need to move towards earlier and more biologically precise diagnosis. Memory services could become more closely connected with imaging and laboratory diagnostics. Radiology departments could play a greater role in both treatment eligibility and ongoing safety monitoring. Infusion services could also become part of dementia treatment pathways in ways that were previously uncommon.
The transition will require planning.
It could mean reviewing workforce capacity, referral processes, diagnostic availability, estates requirements, equipment, procurement, information systems and patient communication.
Perhaps most importantly, services will need to ensure that innovation does not create unnecessary inequality. Access to appropriate diagnosis and care should not depend simply on where somebody lives or how easily they can navigate a complicated healthcare pathway.
FAQ: NHS Alzheimer’s Treatments
Are lecanemab and donanemab cures for Alzheimer’s disease?
No. Lecanemab and donanemab are disease-modifying treatments designed to slow the progression of early Alzheimer’s disease in eligible patients. They do not reverse existing cognitive decline or cure Alzheimer’s disease.
Are the new Alzheimer’s drugs currently available on the NHS?
Lecanemab and donanemab have been licensed in the UK, but they are not currently routinely available through the NHS. NICE has been assessing their clinical and cost effectiveness, including following further consideration during 2026.
Why would the NHS need more diagnostic capacity?
Disease-modifying treatments require careful identification of eligible patients. The potential pathway can include cognitive assessment, MRI and confirmation of amyloid pathology through specialist testing such as PET imaging or lumbar puncture. Treatment can also require further MRI monitoring.
Why is early diagnosis important?
The currently licensed disease-modifying medicines are intended for people in the earlier stages of Alzheimer’s disease. Identifying patients appropriately and promptly is therefore important if these or future therapies become part of routine treatment pathways.
Can healthcare equipment cure or treat dementia?
General healthcare, sensory and dementia-friendly environmental equipment should not be presented as a cure for dementia. Appropriate products can instead support areas such as orientation, comfort, safety, engagement and the creation of more dementia-friendly healthcare environments.
Conclusion
The debate surrounding NHS Alzheimer’s treatments highlights both the extraordinary progress being made in dementia research and the practical challenge of translating scientific breakthroughs into everyday patient care.
Lecanemab and donanemab have demonstrated that slowing the progression of early Alzheimer’s disease is possible, but medicines are only one part of the equation. Earlier diagnosis, specialist testing, MRI capacity, infusion services, safety monitoring, workforce planning and effective procurement all matter if disease-modifying treatment is to become more widely integrated into healthcare.
Even if the immediate NHS access position for individual medicines remains restricted, the direction of dementia research is changing. Healthcare organisations therefore have an opportunity to consider how their services, environments and supply chains may need to evolve.
Niche Healthcare supports NHS organisations and other healthcare providers with specialist healthcare products, procurement support and equipment designed for modern clinical environments. As dementia care develops, reliable healthcare infrastructure and thoughtful procurement will remain essential to ensuring that innovation can be translated into safe, practical and patient-centred care.
For further information about Niche Healthcare and its healthcare product range, visit:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
NHS Alzheimer’s Treatments
See our full selection:
Healthcare Supplies in Aberdeen | Niche Healthcare
Healthcare Supplies in Basildon | Niche Healthcare
Healthcare Supplies in Basingstoke | Niche Healthcare
Healthcare Supplies in London | Niche Healthcare
For procurement details, bulk purchasing, and further product information, contact our team today on 01274 965089 or check out our website at www.nicheofficesolutions.co.uk / www.nicheofficesolutions.co.uk/niche-nhs
Further clinical information can be found on our blog page: www.nicheofficesolutions.co.uk/category/niche-healthcare-news
For products not found on our online website, please view our Healthcare catalogues: www.nicheofficesolutions.co.uk/healthcare-catalogues
View our Healthcare YouTube videos Playlist
If you have any additional questions, drop us an email at info@nicheofficesolutions.co.uk